Developer docs
API playgroundTry for free, no card

Search company profiles

Atelerix

Full company profile

uuid0000gur

Namestring
Atelerix
Legal namestring
Atelerix Ltd
Websiteurl
atelerix.co.uk
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Atelerix Ltd is a UK-based biotechnology company that has developed a proprietary alginate-based hydrogel encapsulation technology enabling hypothermic preservation and ambient-temperature (4–25°C) storage and transport of living biological samples — cells, viruses, viral vectors, LNPs, leukapheresis products, tissues, organoids, spheroids, microtissues, and whole blood — without cryopreservation or cold-chain logistics. The technology, originated at Newcastle University and spun out in 2019, maintains over 90% cell viability for up to 14 days at room temperature and uses a xeno-free, seaweed-derived biopolymer. The company commercializes a portfolio of six trademarked kit products (CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, BloodReady, with BeadReady in earlier use) targeting pharma/biotech R&D, CROs, cell therapy developers, advanced in vitro model companies, and clinical research institutions, with documented enterprise validations from LV Prasad Eye Institute, DefiniGEN/Pixl Bio, Labcorp Drug Development, Johns Hopkins, and LabSkin.

The company is led by CEO Alastair Carrington and CSO/Co-founder Dr Steve Swioklo, holds ISO 9001:2015 certification, and is headquartered at The Biosphere on Newcastle Helix. Atelerix generates revenue through one-time kit sales via its own e-commerce storefront and through an expanding network of exclusive regional distribution partners covering China (MineBio), Middle East with local manufacturing (JH Health), Europe/North Africa (CliniSciences), North America (North Star Scientific), India (BioBench), and Central Europe (Scintila). Pricing is quote-based and not publicly disclosed, but the company offers a money-back guarantee to new customers and free sample kits to drive adoption. Cumulative disclosed funding totals roughly £2.7m across multiple rounds from 2018–2025, with the most recent £750k seed round in January 2025 co-led by ACF Investors and o2h Ventures.

Short descriptiontext

Atelerix is a UK biotech that sells alginate-hydrogel kits enabling ambient-temperature storage and shipping of cells, tissues, viruses, and blood without cryopreservation, serving pharma, CROs, cell therapy developers, and advanced in vitro model companies through direct sales and an exclusive global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell preservation technology, ambient temperature storage, biological sample transport, hypothermic preservation kits, cold chain logistics
Industry2 codes
PRIMARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Preservation Products
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales
TypeOne Time License
Description

Atelerix generates revenue through direct sales of its hydrogel-based preservation products via its e-commerce platform and through distribution partners globally. Products include CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, and BloodReady, sold as kit formats for research and commercial applications.

atelerix.co.uk
2Distribution Partnerships
TypeTransaction Fee
Description

Revenue flows through exclusive distribution agreements with regional partners who purchase products for resale in their territories, including MineBio (China), CliniSciences (Europe/North Africa), and JH Health (Middle East).

atelerix.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Kit-based product pricing with money-back guarantee for new customers
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products are sold in kit format with approximately 1 minute hands-on time required. All new customers receive a money-back satisfaction guarantee.

atelerix.co.uk
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1CytoStor
Description

Transport solution for cells, viruses, viral vectors and LNPs without cryopreservation - no dry ice required

atelerix.co.uk
+6 more records
Core offering1 text field

Atelerix develops and manufactures proprietary alginate-based hydrogel encapsulation kits that preserve and transport living cells, tissues, viruses, viral vectors, and whole blood at ambient temperatures (4-25°C) without cryopreservation or dry ice. The product portfolio includes CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, and BloodReady, sold to pharmaceutical, biotech, CRO, and cell therapy customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 90% cell viability maintained for 14 days at room temperature
+5 more records
Product overview1 text field

Atelerix offers a portfolio of six specialized hydrogel-based cell and tissue preservation products that enable ambient-temperature (4-25°C) storage and transport without cryopreservation. The core technology uses alginate-based hydrogel encapsulation to maintain cell viability for up to 14 days at room temperature. Product lineup includes: CytoStor for cells, viruses, and LNP-mRNA; LeukoStor for leukapheresis in cell therapy workflows; TissueReady Plus for biopsy and resection tissue; STORganoid and WellReady for 3D cell models (organoids, spheroids, microtissues); and BloodReady for whole blood preservation. The technology eliminates the need for dry ice, specialized cryogenic shipping, and ultra-low temperature freezers, reducing shipping costs by 50-80% per shipment.

Product and service2 records
1CytoStor™
CategoryCell preservation kits
Description

Transport cells, viruses, viral vectors, and LNPs without cryopreservation using alginate-based hydrogel encapsulation at 4-25°C; no dry ice required. Encapsulates up to 10 million cells per tube.

2LeukoStor™
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1JH Health Ltd
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Strategic partnership granting exclusive rights to use and distribute Atelerix's portfolio of non-cryogenic preservation solutions in the Middle East. Agreement includes regional manufacturing capabilities, distribution channels, and financial support from JH Health, while Atelerix leads regulatory approvals with the Saudi Food and Drug Authority. Marks Atelerix's second major international expansion following China distribution deal.

business-live.co.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Partnership to integrate non-cryogenic transport solutions with advanced organoid models. The collaboration aims to enable extended transport at ambient or controlled temperatures, reducing reliance on cold-chain logistics and improving global distribution capabilities for organoids. Initial 12-month trial to validate technology performance for potential commercial deployment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Partnership to enable long-distance transport of advanced in vitro skin models without cryopreservation. The agreement aims to broaden access, streamline logistics, and reduce variability associated with temperature-sensitive shipping of 3D tissue models. Labskin's full-thickness model can now be shipped beyond the previous 96-hour window while maintaining model structure.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-01
Description

Partnership to integrate cryo-free preservation technology into specialist logistics solutions for drug discovery and clinical applications. Atelerix's non-cryogenic cell preservation technology is incorporated into Rodon Global's international freight and logistics services, enabling smarter, more sustainable solutions for researchers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

Distribution agreement with specialist life science and diagnostic labs distributor to broaden access to cryo-free preservation solutions across Europe and North Africa. New distribution channels expand global operational reach and market penetration.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Exclusive distribution agreement making MineBio the sole distribution partner for Atelerix products in China. MineBio, a leading Chinese supply chain and logistics organization specializing in gene and cell therapy, regenerative medicine, and biologics, will provide solutions to traditional cryopreservation challenges in the high-growth Chinese market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Collaboration to ship in vitro cell models internationally without the need for freezing or cryopreservation. Successfully shipped iPSC-derived hepatocytes from UK to US fresh in assay-ready plates, eliminating cold chain logistics and enhancing functional assay quality.

8North Star Scientific
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-06-01
Description

Partnership to revolutionize life sciences in North America by distributing Atelerix's preservation technology. North Star Scientific serves as the distribution partner for the North American market.

atelerix.co.uk
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-01
Description

Distribution agreement for Czech Republic and Slovakia. Scintila S.R.O distributes Atelerix products in the Central and Eastern European region.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-09-01
Description

Distribution agreement between Atelerix (UK) and BioBench Solutions LLP (India) for distribution of Atelerix products in the Indian market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration using WellReady technology to transport ImmueOne's ImmuPHAGE alveolar-like macrophages. Collaboration demonstrates robustness of in vitro models and enables successful shipping of cells for lung and immune research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-listed cell preservation and biopreservation tools company offering CryoStor and similar hypothermic/cryopreservation media for cell therapy and regenerative medicine. Direct competitor to Atelerix in cell and tissue preservation reagents, with much larger commercial footprint.

TypeDirect peer
Description

Specialized cold-chain logistics provider for life sciences, including cell therapy supply chains. Competitor in the biosample transport value chain where Atelerix positions its ambient-temperature solution as an alternative to Cryoport's cryogenic shipping infrastructure.

TypeDirect peer
Description

Canada-based developer of cell culture media, separation products, and instruments for life sciences research and cell therapy. Overlaps with Atelerix in cell preservation reagents and primary cell products used in drug discovery and regenerative medicine.

TypeDirect peer
Description

Cell and gene therapy raw materials supplier offering manufacturing cytokines and cell processing reagents. Comparable to Atelerix in supplying critical ancillary materials and preservation solutions used in cell therapy manufacturing workflows.

TypeBroad incumbent
Description

Major life sciences tools company offering cell separation, culture, and processing products used in cell therapy and research. Overlaps with Atelerix in the broader cell preservation and processing workflow, though Miltenyi's portfolio is far broader.

TypeBroad incumbent
Description

Global cell and gene therapy CDMO and bioprocessing solutions provider. Comparable through its cell therapy manufacturing services and ancillary raw materials, representing a much larger incumbent serving similar pharma/biotech customers.

TypeBroad incumbent
Description

Life sciences reagents and tools company with extensive cell culture, primary cell, and tissue product portfolios. Overlaps with Atelerix's customer base in academic and pharmaceutical research, including organoid and cell model workflows.

TypeEmerging player
Description

Specialty supplier of cell isolation, tissue processing, and preservation enzymes and reagents. Comparable niche player in tissue and cell processing tools, serving overlapping research and cell therapy customers.

TypeEmerging player
Description

Niche providers in the organoid preservation and shipping space that compete for share of the same advanced in vitro model logistics market that Atelerix's STORganoid product targets.

TypeOthers
Description

Sample management and cryogenic storage services provider for life sciences and biobanks. Adjacent infrastructure competitor in biosample storage and logistics, serving biopharma and research customers that also use cell preservation reagents.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atelerix

Cell Preservation Productsatelerix.co.uk

Atelerix is a UK biotech that sells alginate-hydrogel kits enabling ambient-temperature storage and shipping of cells, tissues, viruses, and blood without cryopreservation, serving pharma, CROs, cell therapy developers, and advanced in vitro model companies through direct sales and an exclusive global distributor network.

What Atelerix does

Atelerix Ltd is a UK-based biotechnology company that has developed a proprietary alginate-based hydrogel encapsulation technology enabling hypothermic preservation and ambient-temperature (4–25°C) storage and transport of living biological samples — cells, viruses, viral vectors, LNPs, leukapheresis products, tissues, organoids, spheroids, microtissues, and whole blood — without cryopreservation or cold-chain logistics. The technology, originated at Newcastle University and spun out in 2019, maintains over 90% cell viability for up to 14 days at room temperature and uses a xeno-free, seaweed-derived biopolymer. The company commercializes a portfolio of six trademarked kit products (CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, BloodReady, with BeadReady in earlier use) targeting pharma/biotech R&D, CROs, cell therapy developers, advanced in vitro model companies, and clinical research institutions, with documented enterprise validations from LV Prasad Eye Institute, DefiniGEN/Pixl Bio, Labcorp Drug Development, Johns Hopkins, and LabSkin.

The company is led by CEO Alastair Carrington and CSO/Co-founder Dr Steve Swioklo, holds ISO 9001:2015 certification, and is headquartered at The Biosphere on Newcastle Helix. Atelerix generates revenue through one-time kit sales via its own e-commerce storefront and through an expanding network of exclusive regional distribution partners covering China (MineBio), Middle East with local manufacturing (JH Health), Europe/North Africa (CliniSciences), North America (North Star Scientific), India (BioBench), and Central Europe (Scintila). Pricing is quote-based and not publicly disclosed, but the company offers a money-back guarantee to new customers and free sample kits to drive adoption. Cumulative disclosed funding totals roughly £2.7m across multiple rounds from 2018–2025, with the most recent £750k seed round in January 2025 co-led by ACF Investors and o2h Ventures.

Atelerix firmographics

Firmographics
Name
Atelerix
Legal name
Atelerix Ltd
Website
https://atelerix.co.uk
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Atelerix is a UK biotech that sells alginate-hydrogel kits enabling ambient-temperature storage and shipping of cells, tissues, viruses, and blood without cryopreservation, serving pharma, CROs, cell therapy developers, and advanced in vitro model companies through direct sales and an exclusive global distributor network.
Ownership category
akta.pro rank

Atelerix industry classification

Industry
Product category
Cell Preservation Products
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • Cell preservation technology
  • Ambient temperature storage
  • Biological sample transport
  • Hypothermic preservation kits
  • Cold chain logistics

Where Atelerix is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Atelerix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Product Sales: Atelerix generates revenue through direct sales of its hydrogel-based preservation products via its e-commerce platform and through distribution partners globally. Products include CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, and BloodReady, sold as kit formats for research and commercial applications.
  2. Distribution Partnerships: Revenue flows through exclusive distribution agreements with regional partners who purchase products for resale in their territories, including MineBio (China), CliniSciences (Europe/North Africa), and JH Health (Middle East).

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goKit-based product pricing with money-back guarantee for new customers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Atelerix product offering

Product offering

Core offering

Atelerix develops and manufactures proprietary alginate-based hydrogel encapsulation kits that preserve and transport living cells, tissues, viruses, viral vectors, and whole blood at ambient temperatures (4-25°C) without cryopreservation or dry ice. The product portfolio includes CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, and BloodReady, sold to pharmaceutical, biotech, CRO, and cell therapy customers.

Product overview

Atelerix offers a portfolio of six specialized hydrogel-based cell and tissue preservation products that enable ambient-temperature (4-25°C) storage and transport without cryopreservation. The core technology uses alginate-based hydrogel encapsulation to maintain cell viability for up to 14 days at room temperature. Product lineup includes: CytoStor for cells, viruses, and LNP-mRNA; LeukoStor for leukapheresis in cell therapy workflows; TissueReady Plus for biopsy and resection tissue; STORganoid and WellReady for 3D cell models (organoids, spheroids, microtissues); and BloodReady for whole blood preservation. The technology eliminates the need for dry ice, specialized cryogenic shipping, and ultra-low temperature freezers, reducing shipping costs by 50-80% per shipment.

Differentiator

Problem solved

Functional benefit

Brands

  • CytoStor: Transport solution for cells, viruses, viral vectors and LNPs without cryopreservation - no dry ice required
  • LeukoStor
  • TissueReady Plus
  • STORganoid
  • WellReady
  • BloodReady
  • BeadReady

Products and services

  • CytoStor™ Transport cells, viruses, viral vectors, and LNPs without cryopreservation using alginate-based hydrogel encapsulation at 4-25°C; no dry ice required. Encapsulates up to 10 million cells per tube.
  • LeukoStor™

Quantifiable outcome

  • Over 90% cell viability maintained for 14 days at room temperature
  • +5 more outcomes

Companies that use Atelerix

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Atelerix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Atelerix partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

  • JH Health LtdflagshipChannel Partner/ Reseller/ Distributor · 1 April 2026Strategic partnership granting exclusive rights to use and distribute Atelerix's portfolio of non-cryogenic preservation solutions in the Middle East. Agreement includes regional manufacturing capabilities, distribution channels, and financial support from JH Health, while Atelerix leads regulatory approvals with the Saudi Food and Drug Authority. Marks Atelerix's second major international expansion following China distribution deal.
  • Cherry BiotechcoreStrategic or Co-development Partner · 1 December 2025Partnership to integrate non-cryogenic transport solutions with advanced organoid models. The collaboration aims to enable extended transport at ambient or controlled temperatures, reducing reliance on cold-chain logistics and improving global distribution capabilities for organoids. Initial 12-month trial to validate technology performance for potential commercial deployment.
  • LabskincoreStrategic or Co-development Partner · 1 December 2025Partnership to enable long-distance transport of advanced in vitro skin models without cryopreservation. The agreement aims to broaden access, streamline logistics, and reduce variability associated with temperature-sensitive shipping of 3D tissue models. Labskin's full-thickness model can now be shipped beyond the previous 96-hour window while maintaining model structure.
  • Rodon GlobalcoreTechnology or Integration · 1 September 2025Partnership to integrate cryo-free preservation technology into specialist logistics solutions for drug discovery and clinical applications. Atelerix's non-cryogenic cell preservation technology is incorporated into Rodon Global's international freight and logistics services, enabling smarter, more sustainable solutions for researchers.
  • CliniSciencescoreChannel Partner/ Reseller/ Distributor · 1 September 2025Distribution agreement with specialist life science and diagnostic labs distributor to broaden access to cryo-free preservation solutions across Europe and North Africa. New distribution channels expand global operational reach and market penetration.
  • MineBioflagshipChannel Partner/ Reseller/ Distributor · 1 April 2025Exclusive distribution agreement making MineBio the sole distribution partner for Atelerix products in China. MineBio, a leading Chinese supply chain and logistics organization specializing in gene and cell therapy, regenerative medicine, and biologics, will provide solutions to traditional cryopreservation challenges in the high-growth Chinese market.
  • DefiniGENcoreStrategic or Co-development Partner · 1 July 2024Collaboration to ship in vitro cell models internationally without the need for freezing or cryopreservation. Successfully shipped iPSC-derived hepatocytes from UK to US fresh in assay-ready plates, eliminating cold chain logistics and enhancing functional assay quality.
  • North Star ScientificcoreChannel Partner/ Reseller/ Distributor · 1 June 2024Partnership to revolutionize life sciences in North America by distributing Atelerix's preservation technology. North Star Scientific serves as the distribution partner for the North American market.
  • Scintila S.R.OminorChannel Partner/ Reseller/ Distributor · 1 April 2024Distribution agreement for Czech Republic and Slovakia. Scintila S.R.O distributes Atelerix products in the Central and Eastern European region.
  • BioBench Solutions LLPminorChannel Partner/ Reseller/ Distributor · 1 September 2022Distribution agreement between Atelerix (UK) and BioBench Solutions LLP (India) for distribution of Atelerix products in the Indian market.
  • ImmueOneminorStrategic or Co-development PartnerCollaboration using WellReady technology to transport ImmueOne's ImmuPHAGE alveolar-like macrophages. Collaboration demonstrates robustness of in vitro models and enables successful shipping of cells for lung and immune research.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Atelerix competitors and assessment

Company assessment

Direct peers

  • BioLife Solutions: US-listed cell preservation and biopreservation tools company offering CryoStor and similar hypothermic/cryopreservation media for cell therapy and regenerative medicine. Direct competitor to Atelerix in cell and tissue preservation reagents, with much larger commercial footprint.
  • Cryoport Systems: Specialized cold-chain logistics provider for life sciences, including cell therapy supply chains. Competitor in the biosample transport value chain where Atelerix positions its ambient-temperature solution as an alternative to Cryoport's cryogenic shipping infrastructure.
  • STEMCELL Technologies: Canada-based developer of cell culture media, separation products, and instruments for life sciences research and cell therapy. Overlaps with Atelerix in cell preservation reagents and primary cell products used in drug discovery and regenerative medicine.
  • CellGenix: Cell and gene therapy raw materials supplier offering manufacturing cytokines and cell processing reagents. Comparable to Atelerix in supplying critical ancillary materials and preservation solutions used in cell therapy manufacturing workflows.

Broad incumbents

  • Miltenyi Biotec: Major life sciences tools company offering cell separation, culture, and processing products used in cell therapy and research. Overlaps with Atelerix in the broader cell preservation and processing workflow, though Miltenyi's portfolio is far broader.
  • Lonza Group: Global cell and gene therapy CDMO and bioprocessing solutions provider. Comparable through its cell therapy manufacturing services and ancillary raw materials, representing a much larger incumbent serving similar pharma/biotech customers.
  • Bio-Techne: Life sciences reagents and tools company with extensive cell culture, primary cell, and tissue product portfolios. Overlaps with Atelerix's customer base in academic and pharmaceutical research, including organoid and cell model workflows.

Emerging players

  • Worthington Biochemical: Specialty supplier of cell isolation, tissue processing, and preservation enzymes and reagents. Comparable niche player in tissue and cell processing tools, serving overlapping research and cell therapy customers.
  • Organoid Sciences: Niche providers in the organoid preservation and shipping space that compete for share of the same advanced in vitro model logistics market that Atelerix's STORganoid product targets.

Others

  • Brooks Life Sciences: Sample management and cryogenic storage services provider for life sciences and biobanks. Adjacent infrastructure competitor in biosample storage and logistics, serving biopharma and research customers that also use cell preservation reagents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Atelerix social profiles

Digital presence

Atelerix compliance and trust

Trust signal

Compliance1 record

Atelerix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atelerix leadership team

Management profile

Number of profiles

Profiles8 records

Atelerix funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atelerix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atelerix

What does Atelerix do?

Atelerix develops and manufactures proprietary alginate-based hydrogel encapsulation kits that preserve and transport living cells, tissues, viruses, viral vectors, and whole blood at ambient temperatures (4-25°C) without cryopreservation or dry ice. The product portfolio includes CytoStor, LeukoStor, TissueReady Plus, STORganoid, WellReady, and BloodReady, sold to pharmaceutical, biotech, CRO, and cell therapy customers.

Is Atelerix a public or private company?

Atelerix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Atelerix founded?

Atelerix was founded in 2019. It employs 11 to 50 people.

Where is Atelerix based?

Atelerix is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does Atelerix make money?

Two revenue lines are on record. Product Sales are the primary driver. The others are distribution Partnerships.

Who are Atelerix's main competitors?

Direct peers on record are BioLife Solutions, Cryoport Systems, STEMCELL Technologies and CellGenix. Broad incumbents are Miltenyi Biotec, Lonza Group and Bio-Techne. Emerging players are Worthington Biochemical and Organoid Sciences. Brooks Life Sciences is listed as an others.

Does Atelerix have an API?

No public API is recorded for Atelerix.

What industry is Atelerix in?

Atelerix's product category is Cell Preservation Products. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalAtelerix and Frontier Space partner to enable biological sample preservation for space missionsAtelerix and Frontier Space signed a two-year MoU to validate Atelerix's alginate hydrogel encapsulation technology for preserving biological samples during microgravity missions. The partnership aims to reduce reliance on cryogenic storage, potentially saving up to $30,000 in launch costs. Launch opportunities are targeted throughout 2027.Business Wire BlogAtelerix and Frontier Space Partner to Enable Biological Sample Preservation for Space MissionsAtelerix and Frontier Space signed a two-year MoU to validate Atelerix's alginate hydrogel encapsulation technology for preserving biological samples during microgravity missions. The partnership aims to reduce payload mass and launch costs, with targets to save up to $30,000 per launch by removing cryogenic storage. Launch opportunities are targeted for 2027.FinancialContent Business PageAtelerix and Frontier Space Partner to Enable Biological Sample Preservation for Space MissionsAtelerix and Frontier Space signed a two-year MoU to validate Atelerix's alginate hydrogel encapsulation technology for preserving biological samples during microgravity missions. The partnership aims to reduce payload mass and launch costs, with Frontier Space estimating savings of up to $30,000 per launch. Launch opportunities are targeted for 2027.Business LiveNewcastle biotech pioneer Atelerix strikes partnership to pave way for overseas growthNewcastle University spin-out Atelerix has signed a strategic partnership with Saudi Arabian company JH Health Ltd, granting exclusive rights to distribute its hydrogel-based cell and tissue preservation solutions in the Middle East. The agreement includes regional manufacturing capabilities, distribution channels, and financial support from JH Health, while Atelerix will lead regulatory approvals with the Saudi Food and Drug Authority. The deal marks Atelerix's second major international expansion following a similar distribution agreement in China and supports the company's goal of building a global commercial footprint.AETOSWireAtelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Mi...Atelerix announced a strategic partnership with JH Health Ltd to distribute its hydrogel-based cell preservation solutions in the Middle East. JH Health will provide financial support and local manufacturing capabilities, while Atelerix leads regulatory approvals with Saudi authorities. The collaboration aims to expand regional access to non-cryogenic biological sample transport.Business Wire BlogAtelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle EastAtelerix announced a strategic partnership with JH Health, granting the Saudi company exclusive rights to distribute its non-cryogenic cell preservation solutions in the Middle East. The deal includes funding for local high-volume manufacturing, regulatory filings, and research collaborations, with JH Health providing financial support and strategic expertise.News-MedicalAtelerix forms strategic partnership with JH Health Ltd to expand non-cryogenic cell preservation capabilities in the Middle EastAtelerix announced a strategic partnership with Saudi-based JH Health, granting JH Health exclusive rights to distribute Atelerix's hydrogel-based cell preservation solutions in the Middle East. The collaboration includes local manufacturing, regulatory approvals with Saudi authorities, and financial support for scale-up. Atelerix will lead regulatory approvals for its technology.SelectScienceAtelerix partners with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid modelsAtelerix has partnered with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models. This collaboration aims to improve the logistics and effectiveness of organoid research and applications. The advancement in transport solutions is crucial for enhancing the usability and accessibility of organoids in biomedical research.Longevity.TechnologyAtelerix and Cherry Biotech team up on organoid shippingUK-based biotech Atelerix has entered into a partnership with French organoid specialist Cherry Biotech to integrate hydrogel-based biosample transport technology with advanced 3D organoid models, addressing challenges in shipping temperature-sensitive biological materials without conventional cold-chain logistics. The collaboration begins with a 12-month trial period to validate technical performance and strategic fit, building on earlier testing that demonstrated preservation of membrane integrity and biological function during ambient or controlled-temperature transport. The companies aim to lower logistical barriers for laboratories lacking specialized cold-chain infrastructure, particularly in emerging research markets, while reducing costs and environmental footprint.News-MedicalAtelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid modelsAtelerix, a biotech company specializing in cell preservation and biological transport, has entered a partnership agreement with French company Cherry Biotech to integrate its patented hydrogel encapsulation technology with Cherry Biotech's advanced 3D organoid models for global shipment without cold-chain logistics. The initial 12-month trial period will validate the strategic and technical alignment of both companies while enabling worldwide distribution of temperature-sensitive organoid products including Cherry Biotech's recently released organoidPlate. The partnership aims to expand commercial traction and market reach for Atelerix's ambient logistics solutions while strengthening Cherry Biotech's ability to deliver cutting-edge organoid models to pharma and academic researchers globally.